Rory B. Riggs - Mar 29, 2023 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: Director
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Rory B. Riggs
Stock symbol: RPRX
Transactions as of: Mar 29, 2023
Transactions value $: -$5,081,111
Form type: 4
Date filed: 3/30/2023, 05:53 PM
Previous filing: Feb 17, 2023
Next filing: Apr 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Sale	-$367K	-9.93K	-0.62%	$36.95	1.59M	Mar 29, 2023	Direct	F1
transaction	RPRX	Class A Ordinary Shares	Sale	-$4.71M	-130K	-8.19%	$36.26	1.46M	Mar 30, 2023	Direct	F2
holding	RPRX	Class A Ordinary Shares						85.2K	Mar 29, 2023	By New Ventures III LLC
holding	RPRX	Class A Ordinary Shares						15K	Mar 29, 2023	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.18 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.18 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.